These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27801326)

  • 21. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
    Cazzola M; Della Porta MG; Malcovati L
    Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
    Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
    Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA
    Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Influencing factors of iron metabolism assessment in patients with myelodysplastic syndrome: A retrospective study].
    Zhang Y; Xiao C; Li J; Song LX; Zhao YS; Zhao JG; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):293-299. PubMed ID: 35680627
    [No Abstract]   [Full Text] [Related]  

  • 26. High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.
    Teichman J; Geddes M; Zhu N; Keating MM; Sabloff M; Christou G; Leber B; Khalaf D; St-Hilaire E; Finn N; Shamy A; Yee KWL; Storring JM; Nevill TJ; Delage R; Elemary M; Banerji V; Houston B; Mozessohn L; Chodirker L; Zhang L; Siddiqui M; Parmentier A; Leitch HA; Buckstein RJ
    Haematologica; 2023 Feb; 108(2):532-542. PubMed ID: 35979720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C; Clissa C; Stanzani M
    Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron overload in myelodysplastic syndromes.
    Mahesh S; Ginzburg Y; Verma A
    Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.
    Du Y; Long Z; Chen M; Han B; Hou B; Feng F
    Acta Haematol; 2017; 138(2):119-128. PubMed ID: 28866669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.
    Zipperer E; Post JG; Herkert M; Kündgen A; Fox F; Haas R; Gattermann N; Germing U
    Ann Hematol; 2013 Dec; 92(12):1617-23. PubMed ID: 23842708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Laboratory Associations with Persistent Hyperferritinemia in 373 Black Hemochromatosis and Iron Overload Screening Study Participants.
    Barton JC; Barton JC; Adams PC
    Ann Hepatol; 2017; 16(5):802-811. PubMed ID: 28809726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
    Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
    Wong SA; Leitch HA
    Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
    Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S
    Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and treatment of anemia and secondary iron overload in patients with a myelodysplastic syndrome: Real-world data from a multicenter cohort study.
    de Roij van Zuijdewijn CLM; Westerweel PE; Schipperus MR; Pruijt JFM; van de Loosdrecht AA; Beeker A
    Transfus Clin Biol; 2023 Aug; 30(3):314-318. PubMed ID: 37061177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Shammo JM; Komrokji RS
    Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform.
    Valent P; Stauder R; Theurl I; Geissler K; Sliwa T; Sperr WR; Bettelheim P; Sill H; Pfeilstöcker M
    Expert Rev Hematol; 2018 Feb; 11(2):109-116. PubMed ID: 29292655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.